• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 7, 2014

View Archived Issues

Cytori sinks after hold placed on enrollment in ATHENA trials

Shares of Cytori Therapeutics Inc. (NASDAQ:CYTX) fell to a one-year low of $1.46 Wednesday morning after the company disclosed late Tuesday that it placed a clinical hold on enrollment in the phase II ATHENA and ATHENA II trials of its adipose-derived regenerative cells (ADRCs) in heart failure patients. Read More

Stem cell survival factor could improve bone marrow transplants

LONDON – The ability to boost the efficiency of bone marrow transplantations – and possibly allow bone marrow and cord-blood transplantation in people who previously would not have been considered suitable candidates – could follow from a new understanding of how to stimulate hematopoietic stem cells. Read More

EARS opens on Nasdaq; Auris nets $51M in IPO

Auris Medical Holding AG netted $51 million in a bargain basement initial public offering (IPO), comprising 9.4 million shares priced at $6 per share. Gross proceeds were $56.4 million, whereas the Zug, Switzerland-based firm originally planned to raise as much as $82.8 million, by offering 6.9 million shares, priced at $10 to $12 per share. Read More

Sotio opens lab in Beijing to treat prostate, lung cancer patients

SHANGHAI – Sotio AS, of Prague, has expanded its China footprint with the opening of a GMP, clean-room lab for the production of active cellular immunotherapy treatments against cancer diseases. This is their second facility, giving them a combined lab space of 1,000 square meters in Beijing. Sotio will produce therapeutic cellular treatments for patients with prostate and lung cancer. Read More

Enumeral joins OTCQB with $21.5M private placement

Enumeral Biomedical Holdings Inc., an early stage immunomodulator discovery and development venture, has transitioned to the OTCQB through a reverse merger with a shell company simultaneous with the close of a $21.5 million equity financing. Read More

Anti-neoteny botany: Alder takes on Lilly as migraine CGRPs reach maturity fast

Alder Biopharmaceuticals Inc. and Eli Lilly and Co. stand as the only developers of calcitonin gene-related peptide (CGRP) blockers that have generated human efficacy data in migraine patients, but Amgen Inc. and Teva Pharmaceuticals Ltd. are courting similar phase II success in the clinic. Read More

Earnings

Jazz Pharmaceuticals plc, of Dublin, reported total revenues for their second quarter ended June 30, 2014, were $291.2 million, an increase of 40 percent over total revenues of $208.3 million for the second quarter of 2013. Read More

Stock movers

Read More

Financings

Avalanche Biotechnologies Inc., of Menlo Park, Calif., said it closed its initial public offering (IPO) of 6,900,000 shares of its common stock at $17 each, which included the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares of common stock. Read More

Other news to note

Celgene Corp., of Summit, N.J., said Health Canada approved Abraxane for injectable suspension (nab-paclitaxel powder for injectable suspension) in combination with gemcitabine as first-line treatment for adults with metastatic pancreatic cancer, based on the results of the phase III MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial) study of 861 chemotherapy-naïve patients with metastatic pancreatic cancer from 11 countries, including Canada. Read More

In the clinic

Cara Therapeutics Inc., of Shelton, Conn., disclosed the dosing of the first dialysis patients in a phase II trial of an intravenous formulation of its peripherally selective kappa opioid agonist, CR845, for the treatment of uremic pruritus. The company expects to report top-line data from this trial in the first half of 2015. Read More

Pharma: Other news to note

Yabao Pharmaceutical Co. Inc., of Beijing, signed a strategic partnership with Changzhou Le Sun Pharmaceuticals Ltd., of Changzhou, China, to co-develop Le Sun's leading PLK/PI3K dual inhibitor LS-008, which currently is in preclinical development. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 22, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 22, 2025.
  • Brain and neural networks

    Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

    BioWorld
    The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 22, 2025
  • Pfizer describes new STAT6 inhibitors

    BioWorld Science
    Pfizer Inc. has identified signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of Alzheimer’s disease,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe